Low bone mass in prepubertal children with thalassemia major: Insights into the pathogenesis of low bone mass in thalassemia

Journal of Pediatric Endocrinology and Metabolism

Volumn 17, Issue 10, 2004, Pages 1415-1421

  Vogiatzi, Maria G ^a   Autio, Karen A ^a   Schneider, Robert ^b   Giardina, Patricia J ^a,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c NONE   (United States)

Author keywords

Bone mineral density; Bone resorption; Osteopenia; Osteoporosis

Indexed keywords

DEFEROXAMINE MESYLATE; FERRITIN; LIVER ENZYME;

ARTICLE; BLOOD TRANSFUSION; BODY HEIGHT; BODY WEIGHT; BONE DEFORMATION; BONE DENSITY; BONE MASS; BONE MINERAL; CHILD; CHILD GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOCRINE DISEASE; FEMALE; FERRITIN BLOOD LEVEL; GENOTYPE; HUMAN; IRON CHELATION; MALE; PATHOGENESIS; PREPUBERTY; SCORING SYSTEM; THALASSEMIA MAJOR; VERTEBRA;

EID: 7244236521     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2004.17.10.1415     Document Type: Article

References (29)

1. Cooley TB, Lee P. A series of cases of splenomegaly in children with anemia and peculiar bone changes. Trans Am Pediatr Soc 1925; 37: 29-30.
2. Weatherall DJ, Clegg, JB. Thalassemia-a global public health problem. Nature Med 1996; 2: 847-849.
3. Wolman IJ, Ortalani M. Some clinical features of Cooley's anemia patients as related to transfusion schedules. Ann NY Acad Sci 1969; 105: 407.
4. Piomelli S. The management of patients with Cooley's anemia: transfusions and splenectomy. Semin Hematol 1995; 32: 262-268.
5. Giardina PJ, Schneider R, Lesser M, Simmons B, Rodriguez A, Gertner J, New M, Hilgartner MW. Abnormal bone metabolism in thalassemia. In: Andro S, Brancati C, eds. Endocrine Disorders in Thalassemia. Heidelberg: Springer-Verlag, 1995; 39-46.
6. Wonke B, Hoffbrand AV, Bouloux P, Jensen C, Telfer P. New approaches to the management of hepatitis and endocrine disorders in Cooley's anemia. Ann NY Acad Sci 1998; 850: 232-241.
7. DeSanctis V, Vullo C, Katz M, Wonke B, Tanas R, Bagni B. Gonadal function in patients with β-thalassemia major. J Clin Pathol 1988; 41: 133-137.
8. Anapliotou MLG, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitrou P. The contribution of hypogonadism to the development of osteoporosis in thalassemia major: new therapeutic approaches. Clin Endocrinol 1995; 42: 279-287.
9. Soliman AT, El Banna N, Fattah MA, El Zalabani MM, Ansari BM. Bone mineral density in prepubertal children with β-thalassemia: correlation with growth and hormonal data. Metabolism 1988; 47: 541-548.
10. Katz K, Horev G, Goshen J, Tamary H. The pattern of bone disease in transfusion-dependent thalassemia major patients. Isr J Med Sci 1994; 30: 577-580.
11. Filosa A, Di Maio S, Vocca S, Saviano A, Esposito G, Pagano L. Longitudinal monitoring of bone mineral density in thalassemia patients: genetic structure and osteoporosis. Acta Paediatr 1997; 86: 342-346.
12. Rioja L, Girot R, Garabedian M, Gournot-Witmer G. Bone disease in children with homozygous β-thalassemia. Bone Miner 1990; 8: 69-86.
13. Dresner Pollak R, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW. Bone mineral metabolism in adults with β-thalassaemia major and intermedia. Br J Haematol 2000; 111: 902-907.
14. Wonke B, Jensen C, Hanslip JJ, Prescott E, Lalloz M, Layton M, Erten S, Tuck S, Agnew JE, Raja K, Davies K, Hoffbrand AV. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 1998; 11 (Suppl 3): 795-801.
15. Del Rio L, Carrascosa A, Pons F, Gusinye M, Yeste D, Domenech FM. Bone mineral density of the lumbar spine in White Mediterranean Spanish children and adolescents: changes related to age, sex and puberty. Pediatr Res 1994; 35: 362-366.
16. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, Prescott E, Hoffbrand AV, Wonke B. High prevalence of low bone mass in thalassaemia major. Br J Haematol 1998; 103: 911-915.
17. Lassman MN, O'Brien RT, Pearson HA, Wise JK, Donabedian RK, Felig P, Genel M. Endocrine evaluation in thalassemia major. Ann NY Acad Sci 1974; Z32: 226-237.
18. Molyvda-Athanasopoulou E, Sioundas A, Karatzas N, Aggellaki M, Pazaitou K, Vainas I. Bone mineral density of patients with thalassemia major: four-year follow-up. Calcif Tissue Int 1999; 64: 481-484.
19. Kletzky OA, Costin G, Marrs RP, Bernstein G, March CM, Mishell DR Jr. Gonadotropin insufficiency in patients with thalassemia major. J Clin Endocrinol Metab 1979; 48: 901-905.
20. Bachrach LK. Acquisition of optimal bone mass in childhood and adolescence. Trends Endocrinol Metab 2001; 12: 22-28.
21. Soliman AT, El Banna N, Ansari BM. GH response to provocation and circulating IGF-binding protein-3 concentrations, the IGF-1 generation test and the clinical response to GH therapy in children with β-thalassemia. Eur J Endocrinol 1998; 138: 394-400.
22. Pintor C, Celia SG, Manso P, Corda R, Dessi C, Locatelli V, Muller EE. Impaired growth hormone (GH) response to GH-releasing hormone in thalassemia major. J Clin Endocrinol Metab 1986; 62: 263-267.
23. Postel-Vinay MC, Girot R, Leger J, Hocquette JF, McKelvie P, Amar-Costesec A, Rappaport R. No evidence for a defect in growth hormone binding to liver membranes in thalassemia major. J Clin Endocrinol Metab 1989; 68: 94-98.
24. Kurland ES, Rosen CJ, Cosman F, McMahon D, Chan F, Shane E, Lindsay R, Dempster D, Bilezikian JP. Insulin-like growth factor-1 in men with idiopathic osteoporosis. J Clin Endocrinol Metab 1997; 82: 2799-2805.
25. Kurland ES, Chan FKW, Rosen CJ, Bilezikian JP. Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 1998; 3: 2576-2579.
26. Gertner JM, Broadus AE, Anast CS, Grey M, Pearson H, Genel M. Impaired parathyroid response to induced hypocalcemia in thalassemia major. J Pediatr 1979; 95: 210-213.
27. DeVirgilis S, Congia M, Frau F, Argiolu F, Diana G, Cucca F, Varsi A, Sanna G, Poda G, - Fodde M. Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr 1998; 113: 661-669.
28. Giardina PJ, Grady RW. Chelation therapy in β-thalassemia: the benefits and limitations of desferrioxamine. Semin Hematol 1995; 32: 304-312.
29. Brill PW, Winchester P, Giardina PJ, Cunningham-Rundles S. Deferoxamine-induced bone dysplasia in patients with thalassemia major. Ain J Roentigenol 1991; 156: 561-565.